Page 2 - Multiple Ascending Dose News Today

Operator: Good day, and thank you for standing by. Welcome to the Roivant Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support accelerated development of its innovative retinal disease pipelineCompletes enrollment of Multiple Ascending Dose phase...

Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S a biotechnology company focused...

Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma...

Regulus Therapeutics Inc (NASDAQ: RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) trial of RGLS8429 for Autosomal Dominant Polycystic 

Regulus Therapeutics Inc. (RGLS) saw an 8% increase in its shares on Wednesday after announcing the completion of patient enrollment in the second cohort of the Phase 1b Multiple-Ascending Dose (MAD) study of RGSL8429 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD).

AlzeCure Publishes the Positive Clinical Results from the Phase I Trial ...

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

/PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic...

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing (OGTT),